Advertisement

Topics

Companies Related to "Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-Study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)" [Most Relevant Company Matches] RSS

10:58 EDT 23rd October 2018 | BioPortfolio

Here are the most relevant search results for "Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-Study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)" found in our extensive corporate database of over 50,000 company records.

Showing "Insulin Glargine Type Diabetes Mellitus Main Study quot" Companies 1–25 of 1,800+

Extremely Relevant

MannKind

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, Technosphere® Insulin System, is currently in phase 3 clinical trials in the U.S. and Europe to study its safety and efficacy in the treatment of diabetes. This therapy consists of a propri...


Mellitus Health, Inc.

Mellitus Health automates algorithmic dosing of insulin, offering clinicians precision recommendations in seconds. Founded in 2014 as Insulin Algorithms by Mayer B. Davidson, MD, Josh Davidson and Michael Margolese, the Los Angeles firm rebranded in 2018 as Mellitus Health, Inc.

Mellitus Health

Founded in 2014 as Insulin Algorithms by Mayer Davidson, MD, Josh Davidson and Michael Margolese, the Los Angeles firm rebranded in 2018 as Mellitus Health, Inc. Its cloud-based insulin titration software works with all insulins and combinations and all 125 dosing regimens, providing precision insulin dosing recommendations to clinicians in just seconds. T...


DreaMed Diabetes

DreaMed Diabetes was established in 2014 to develop and commercialize diabetes treatment and management solutions. Its flagship product, GlucoSitter™, is a closed-loop insulin delivery system for patients with type 1 and type 2 diabetes. Additional development programs include insulin-treatment-profiling systems for diabetic clinics, patient decision-...

Medtronic Diabetes

At Medtronic Diabetes, our 20 plus year history vividly reflects our dedication and ongoing vision to develop an "artificial pancreas". In 1983, we pioneered the idea of continuous insulin delivery, introducing our first insulin pump in an effort to find a "better way" to deliver insulin for people with diabetes. Since that time, Medtronic Diabetes has remained the market leader, earning a reputat...

Mellitus, LLC

Mellitus is dedicated to advancing diabetes detection and monitoring through products based on GCD59, a biomarker of glycemic load that is unique because of its direct relationship to the complications of diabetes. Our premier application is a patient-friendly test for gestational diabetes, enabling more timely intervention to improve the health of both mo...

Tandem Diabetes Care®, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim® Insulin Pump, the slimmest and smallest durable insulin pump current...

Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. The Company manufactures and sells the t:slim® Insulin Pump, the slimmest and smallest durable insulin pump current...

Bigfoot Biomedical, Inc.

Bigfoot Biomedical was founded by a team of people with a personal connection to type 1 diabetes and, with its Loop and Inject services, seeks to change the paradigm of care for insulin-requiring diabetes by leveraging data, connectivity, automation, and machine learning to reduce the burden on people with insulin-requiring diabetes and maximize the levera...

Waratah Pharmaceuticals

Waratah is a dynamic young biopharmaceutical company founded in April 2000 as a spin-off of RTP Pharma Inc. to develop and commercialize products for its novel, patented therapy – Islet Neogenesis Therapy (I.N.T.™) for the treatment of insulin-dependent diabetes. Diabetes is a disease in which the body does not produce or properly use insulin because of damaged or destroyed insulin producing i...

Glucox Biotech AB

The primary goal of Glucox Biotech is to develop a clinically applicable therapeutic drug for treatment of type 2 diabetes and insulin resistance. The highly favorable benefits of Glucox Biotech therapy is to decrease the critical risks and delay progression of the complications in Type 2 Diabetes patients by improving glycemic blood control. Based on its scientific excellence and with a strong mi...

Dance Pharma

Dance is a San Francisco based, global company focused exclusively on creating a line of small, patient friendly, pain-less, low cost insulin inhalers for the world diabetes market. In addition to providing inhaled insulin to those who have become insulin dependent, the company also intends to enable introduction of insulin much earlier in the disease proc...

Novocell, Inc.

Novocell is a preclinical therapeutic company focused on diabetes. Our therapy is based on the encapsulation and implantation of pancreatic beta cell progenitors (Pro-Islet-1) derived from human stem cells which secrete insulin in patients. Our goal is that Pro-Islet-1 can free both Type 1 and Type 2 diabetic patients from insulin dependence on a long term basis, while reducing or eliminating hy...

Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin formulation, and hepatic (liver) glucose metabolism, the companyâ€...

Relevant

ImmunoMolecular Therapeutics

IM Therapeutics is developing personalized immuno-therapeutic drugs for autoimmune diseases based on the genetic risk attributed by human leukocyte antigen genes. The lead candidate drug is an oral small molecule that starves the autoimmune process in type 1 diabetes by blocking DQ8 on specific immune cells. Our goal is to preserve pancreatic beta cell fun...

Hygieia, Inc.

Hygieia, Inc. is an emerging diabetes health care company developing new ways to improve the effectiveness of therapy while reducing the cost of diabetes care. Hygieia’s first product is a handheld Diabetes Insulin Guidance System (DIGS™) designed to improve insulin therapy effectiveness for patients. DIGS works in a way that makes it a feasible ...

KeyVive.com

KeyVive (pronounced "key veev") derives from the French term "qui vive" and means "one who lives." The mission of KeyVive is to help people affected by diabetes succeed in living a healthy life by educating, informing and connecting individuals to each other. The Web site concept was conceived by Aimee and David Greenholtz as part of their effort to support those affected by diabetes. Aimee was di...

Apofore Corporation

Apofore Corporation is a focused company founded by Patrick Tso, PhD and funded by HealthCare Ventures. ApoA-IV, the first therapeutic being prepared for clinical trials, has promising pre-clinical data supporting potential use in patients with Type 2 diabetes mellitus. For more information, please visit www.apofore.com.

Diabetes Hands Foundation

TuDiabetes.org was co-founded in 2007 by Manny Hernandez, a diabetes advocate and social media expert diagnosed with type 1 diabetes in 2002. The community is run by the Diabetes Hands Foundation, a 501c3 nonprofit that connects people touched by diabetes and raises diabetes awareness.

Team Type 1 Foundation

Established in 2013, the Team Type 1 Foundation is a nonprofit organization pursuing a mission of education, empowerment and equal access to medicine for everyone affected by diabetes. Collaborating with governments, healthcare professionals, diabetes experts and individuals living with diabetes around the world, the Team Type 1 Foundation is bridging the ...

Insulet Corporation

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a revolutionary and easy-to-use tubeless insulin pump tha...

Kadimastem Ltd.

Kadimastem is a biotechnology company focusing on the development and industrial commercialization of products based on human pluripotent stem cells. Kadimastem’s technology in embryonic stem cells serves for the production of unique human cells and tissue for two main types of medical applications:(1) A drug screening platform, which uses stem cell-d...

Metabolex, Inc.

Metabolex is dedicated to the discovery and development of novel therapeutics that will transform the treatment of diabetes and related metabolic disorders. We have created the largest database of genes involved in the disease and have used the information to generate a pipeline of potentially ground-breaking diabetes treatments.Our lead drug candidate, metaglidasen, is a novel, oral insulin sensi...

The T1D Exchange

The T1D Exchange is a unique platform for collaborative data collection and sharing that consists of three overlapping components: a clinic-based registry with clinical, biological and other real-life information from individuals with type 1 diabetes, a registry that is coordinated through a network of clinical centers and an interactive online community f...

T1D Exchange

T1D Exchange was founded on the belief that people affected by type 1 diabetes need better solutions faster – better treatments and better care. Our nonprofit organization takes an innovative approach that puts the community of people touched by type 1 diabetes at the center of research that will meaningfully impact their lives. Our integrated model ...


More From BioPortfolio on "Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-Study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks